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Visual Abstract
Oligodendrocyte progenitor cells (OPCs) are the principal source of new myelin in the central nervous system. A
better understanding of how they mature into myelin-forming cells is of high relevance for remyelination. It has
recently been demonstrated that during developmental myelination, the DNA methyltransferase 1 (DNMT1), but
not DNMT3A, is critical for regulating proliferation and differentiation of OPCs into myelinating oligodendrocytes
Significance Statement
The regenerative therapy of enhancing remyelination is the subject of much current investigation for a
number of central nervous system disorders. However, its mechanisms remain incompletely understood. A
recent study identified a distinct role of the DNAmethyltransferase 1 (DNMT1) in developmental myelination;
here we report a dominant role for DNMT3A in adult remyelination after lysolecithin-induced demyelination.
Overall, this is of high relevance, as it indicates that neonatal and adult oligodendrocyte progenitor cells
might be characterized by distinct epigenetic landscapes that may need to be taken into consideration for
the development of future therapeutic strategies.
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(OLs). However, it remains to be determined whether DNA methylation is also critical for the differentiation of adult
OPCs during remyelination. After lysolecithin-induced demyelination in the ventrolateral spinal cord white matter
of adult mice of either sex, we detected increased levels of DNA methylation and higher expression levels of the
DNA methyltransferase DNMT3A and lower levels of DNMT1 in differentiating adult OLs. To functionally assess
the role of DNMT1 and DNMT3 in adult OPCs, we used mice with inducible and lineage-specific ablation of
Dnmt3a and/or Dnmt1 (i.e., Plp-creER(t);Dnmt3a-flox, Plp-creER(t);Dnmt1-flox, Plp-creER(t);Dnmt1-flox;Dnmt3a-
flox). Upon lysolecithin injection in the spinal cord of these transgenic mice, we detected defective OPC
differentiation and inefficient remyelination in the Dnmt3a null and Dnmt1/Dnmt3a null mice, but not in the Dnmt1
null mice. Taken together with previous results in the developing spinal cord, these data suggest an age-
dependent role of distinct DNA methyltransferases in the oligodendrocyte lineage, with a dominant role for
DNMT1 in neonatal OPCs and for DNMT3A in adult OPCs.
Key words: Adult oligodendrocyte progenitor cells; DNA methylation; remyelination
Introduction
In demyelinating disorders, such as multiple sclerosis
(MS), loss of myelin sheaths disturbs axonal conduction
and trophic support, eventually leading to irreversible ax-
onal loss and disease progression (Trapp et al. 1998;
Nave and Trapp, 2008; Franklin et al. 2012). Remyelination,
which restores myelin sheaths to demyelinated axons and
thereby restores both axonal function and protection, is re-
garded as a promising way to prevent disease progres-
sion (Dubois-Dalcq et al. 2008; Franklin and Ffrench-
Constant, 2008). Oligodendrocyte progenitor cells (OPCs)
have been identified as the main source for new myelin
formation in the adult central nervous system (CNS;
Zawadzka et al. 2010). Therefore, a better understanding
of the molecular mechanism regulating their differentia-
tion into myelin-forming cells is highly desirable. It has
been proposed that after demyelination, adult OPC differ-
entiation recapitulates developmental myelination to a
large extent, and the expression of well-established dif-
ferentiation regulatory transcription factors (e.g., Myrf,
Nkx2.2, Tcf4, Sox2) has been shown to change during
remyelination (Fancy et al. 2004, 2009; Koenning et al.
2012; Moyon et al. 2015; Zhao et al. 2015).
The importance of posttranslational histone modifica-
tions during remyelination has previously been reported
(Shen et al. 2008). Recently, it has been shown that DNA
methylation mediated by the DNA methyltransferase
DNMT1 is essential for developmental myelination, where
it controls the transition from the proliferative OPC stage
to differentiating oligodendrocytes (OLs; Moyon et al. 2016).
In this study, we asked whether similar epigenetic mech-
anisms might be involved in the regulation of adult OPC
differentiation during remyelination. Transcriptomic data
gathered from laser microdissected regions of CNS white
matter at various times after acute experimentally induced
demyelination indicate that the expression of Dnmt1 and
Dnmt3a are differentially regulated during remyelination
(Huang et al. 2011). Both enzyme levels were higher at 5
days post-lesion (dpl), during the early stages of remyeli-
nation, and lower at 14 and 28 dpl, suggesting that DNA
methylation might also play a role in the transition from
adult OPCs to myelinating OLs. A recent study has pre-
viously reported genome-wide DNA methylation changes
in postmortem brain samples from MS patients compared
with controls, suggesting an underlying dysregulation of
DNA methylation in MS brains (Huynh et al. 2014).
This study directly addresses the role of DNA methyl-
ation in oligodendroglial lineage cells during remyelination
in the adult spinal cord. Here we show that DNA methyl-
ation and DNA methyltransferase levels are differentially
regulated during remyelination. We use lineage-specific
inducible genetic ablation of Dnmt1 or Dnmt3a in adult
mice to address the functional relevance of DNA methyl-
ation perturbations for adult OPC differentiation and the
efficiency of remyelination after experimentally induced
demyelination.
Materials and Methods
Animals
All experiments were performed according to institutional
animal care and use committee–approved protocols and
mice were maintained in a temperature- and humidity-
controlled facility on a 12-h light-dark cycle with food and
water ad libitum. Dnmt1fl/fl (Fan et al. 2001; Jackson-Grusby
et al. 2001, RRID:MMRRC_014114-UCD) and Dnmt3afl/fl
(Kaneda et al. 2004, RRID:MGI:3718448) mice on a C57BL/6
background were crossed with Plp-creER(t) (The Jackson
Laboratory, RRID:MGI:3696409; Doerflinger et al. 2003).
Lysolecithin injections
Injections were conducted in the ventrolateral spinal
cord white matter of 8-week-old animals of either sex, as
previously described (Fancy et al. 2009). Briefly, anesthe-
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sia was induced and maintained with inhalational isoflu-
rane/oxygen. The vertebral column was fixed between
metal bars on stereotaxic apparatus. The spinal vertebra
was exposed, tissue was cleared overlying the interverte-
bral space, and the dura was pierced. A pulled-glass
needle was advanced through the spine, at an angle of
70°, and 1 l of 1% lysolecithin (Sigma-Aldrich L4129)
was slowly injected into the ventrolateral white matter.
Mice were sutured and kept in a warm chamber during
recovery.
Tamoxifen injections
4-Hydroxytamoxifen (Sigma-Aldrich T56-48) was dis-
solved at 40 mg/ml in 10% ethanol and 90% corn oil
(Sigma-Aldrich C8267) for 4 h at 37°C with rotation, and
10 mg was administered by gavage to each mouse at
days 3, 5, and 7 (for 14 dpl analysis) or at days 5, 7, and
9 (21 dpl analysis) after lysolecithin injection (day 0).
Immunohistochemistry
For immunohistochemistry, animals were perfused at 5,
14, or 21 dpl with 4% paraformaldehyde and postfixed
overnight in the same solution at 4°C. Spinal cords were
dissected, cryoprotected in sucrose solutions, and frozen
embedded in OCT. Immunohistochemistry was per-
formed on 12-m cryostat sections. Antigen retrieval was
performed for 5-methylcytosine (5mC) staining by incu-
bating slides in subboiling (94°C) citrate buffer (pH 6.0) for
15 min. Slides were incubated in blocking buffer (5%
normal donkey serum in PBS/Triton X-100 0.3%) for 1 h at
room temperature and then overnight at 4°C with the
primary antibodies diluted in a similar blocking buffer (5%
normal donkey serum in PBS/Triton X-100 0.3%). After
rinsing with PBS 1, sections were incubated with the
Alexa Fluor secondary antibodies and then washed with
PBS 1. Cell nuclei were counterstained with DNA fluo-
rescent dye Hoechst 33342 (Sigma B2261) in PBS.
Stained tissue or cells were coverslipped in FluorSave
mounting medium (Millipore 345789) and examined on a
Zeiss Axio Observer fluorescence microscope. To quan-
tify the data generated by immunohistochemical staining,
counts were undertaken by an observer who was blinded
to the experimental group from which the sample being
analyzed was taken. Counts were made throughout the
entire lesion area which was scanned using the 20
objective of the fluorescence microscope. Labeled cells
were manually counted from the images captured under
the same exposure conditions. AxioVision Rel4.8 software
(RRID:SCR_002677) was used for colocalized color iden-
tification and area measurement. Quantification of total
cell number, as defined by nuclear (DAPI) staining, was
assessed both within the lesion area and within the cor-
responding region of white matter in unlesioned tissue.
Table 1. Statistical analysis
Code Data structure Type of test 95% CI
a (Fig. 1C) Normal distribution, equal variances ANOVA and Bonferroni posttests 108.6 to 272.7, –27.42 to 136.7 and –73.69 to 90.40
b (Fig. 1D) Normal distribution, equal variances ANOVA and Bonferroni posttests 51.11 to 98.17 and 11.76 to 58.82 (5dpl); 33.78 to 80.84 and
–11.49 to 35.57 (14dpl); 25.89 to 72.95 and –14.29 to 32.77
(21dpl)
c (Fig. 1F) Normal distribution, equal variances ANOVA and Bonferroni posttests 45.42 to 116.2, 176.9 to 247.7 and 133.9 to 204.7
d (Fig. 1G) Normal distribution, equal variances ANOVA and Bonferroni posttests –2.914 to 37.65 and 60.67 to 101.2 (5dpl); –5.602 to 34.96
and 77.53 to 118.1 (14dpl); –13.63 to 26.93 and 53.74 to 94.30
(21dpl)
e (Fig.1I) Normal distribution, equal variances ANOVA and Bonferroni posttests –73.29 to –34.94, –70.07 to –31.72 and –85.01 to –46.66 (low);
19.25 to 57.60, 8.444 to 46.79 and 16.22 to 54.56 (medium);
–4.294 to 34.05, 4.099 to 42.45, 11.27 to 49.62 (high)
f (Fig. 2B) Normal distribution, equal variances Student’s t-test 201.1 to 231.7 (OLIG2), 191.3 to 215.4 (CC1)
g (Fig. 2D) Normal distribution, equal variances Student’s t-test 210.2 to 205.7 (OLIG2), 203.9 to 189.2 (CC1)
h (Fig. 2F) Normal distribution, equal variances Student’s t-test 178.2 to 144.9 (OLIG2), 165.7 to 136.2 (CC1)
i (Fig.2H) Normal distribution, equal variances ANOVA and Bonferroni posttests 70.83 to 72.29 (low); 15.67 to 13.36 (medium); 13.50 to 14.35 (high)
j (Fig.2I) Normal distribution, equal variances ANOVA and Bonferroni posttests 77.96 to 65.61 (low); 15.85 to 23.22 (medium); 6.186 to 11.17 (high)
k (Fig.2J) Normal distribution, equal variances ANOVA and Bonferroni posttests 67.91 to 58.45 (low); 21.32 to 31.39 (medium); 10.77 to 10.16 (high)
l (Fig. 3B) Normal distribution, equal variances Student’s t-test –307.8 to 246.4 (OLIG2), –249.9 to 105.2 (CC1) and –16.51 to
17.07 (CC1/OLIG2)
m (Fig. 3D) Normal distribution, equal variances Student’s t-test –341.1 to 431.1 (OLIG2), 13.87 to 270.7 (CC1) and 2.758 to
17.22 (CC1/OLIG2)
n (Fig. 3F) Normal distribution, equal variances Student’s t-test –275.5 to 52.4 (OLIG2), 12.91 to 264.6 (CC1) and 17.64 to
38.55 (CC1/OLIG2)
° (Fig. 3G) Normal distribution, equal variances Student’s t-test 36.15 to 226.8 (DNMT1) and –136.3 to 15.88 (DNMT3A); –134.3 to
–21.63 (DNMT1) and 48.69 to 246.2 (DNMT3A); 51.76 to 317.0
(DNMT1) and 106.9 to 307.9 (DNMT3A)
p (Fig.4B) Normal distribution, equal variances ANOVA and Bonferroni posttests 22.94 to 25.45 (low); 59.72 to 59.83 (medium); 17.33 to 14.72 (high)
q (Fig.4D) Normal distribution, equal variances ANOVA and Bonferroni posttests 22.71 to 31.26 (low); 58.99 to 55.91 (medium); 18.30 to 12.83 (high)
r (Fig.4F) Normal distribution, equal variances ANOVA and Bonferroni posttests 21.26 to 37.88 (low); 61.43 to 49.48 (medium); 17.31 to 12.64 (high)
s (Fig. 5B) Nonnormal distribution Nonparametric Mann Whitney test 2.648 to 11.35 and 1.362 to 7.838
t (Fig. 5C) Normal distribution, unequal variances Student’s t-test with Welch’s
correction
–0.005297 to 0.005700
u (Fig. 5E) Nonnormal distribution Nonparametric Mann Whitney test 1.823 to 11.38 and 2.191 to 9.142
v (Fig. 5F) Normal distribution, unequal variances Student’s t-test with Welch’s
correction
–0.001182 to 0.01204
x (Fig. 5H) Nonnormal distribution Nonparametric Mann Whitney test –1.006 to 9.256 and 2.886 to 6.864
y (Fig. 5G) Normal distribution, unequal variances Student’s t-test with Welch’s
correction
–0.01370 to –0.003870
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Figure 1. DNA methyltransferases are differently expressed in adult OPCs during remyelination. A, Schematic of the lysolecithin-
induced focal demyelination and of the area of NWM used for quantification. B, Representative DNMT1, NKX2.2, and CC1 stainings
in NWM and at 5, 14, and 21 dpl (white arrowheads indicate double-positive cells). C, Quantification of the number of double DNMT1
and NKX2.2 cells at 5, 14, and 21 dpl, compared with NWMa. D, Quantification of the percentage of double DNMT1 and NKX2.2
or CC1 cells at 5, 14, and 21 dpl, compared with NWMb. E, Representative DNMT3A, NKX2.2, and CC1 stainings in NWM and at
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To assess the levels of 5mC in OLIG2 cells, arbitrarily
defined as being either low, medium, or high, a macro was
created in ImageJ (RRID:SCR_003070) that first localized
the OLIG2 (red) nuclei and then measured the intensity
of the 5mC (green) staining within the nuclear area. The
intensity value was then normalized by deducting the
background staining intensity. For all quantifications, a
minimum of three sections of 12-m thickness from each
lesion randomly chosen from n  4–6 mice was exam-
ined. The percentage or density of cells was determined
per mouse. The average and standard error was then
calculated for each group using GraphPad Prism (Graph-
Pad, RRID:SCR_002798).
Antibodies
Primary antibodies used are: mouse anti-5mC (Abcam,
ab10805, RRID:AB_442823, 1:200), mouse anti-CC1/APC
(Millipore OP80, RRID:AB_2057371, 1:300), rabbit anti-
DNMT1 (Abcam, ab19905, RRID:AB_731983, 1:1000),
rabbit anti-DNMT3A (Santa Cruz, sc-20703, RRID:
AB_2093990, 1:500), mouse anti-NKX2.2 (Developmental
Studies Hybridoma Bank, University of Iowa, Iowa City,
IA, 1:100), and rabbit anti-OLIG2 (Millipore, ab9610, RRID:
AB_10141047, 1:1000). Alexa Fluor–conjugated second-
ary antibodies (1:5000) were used (Invitrogen).
Electron microscopy
For electron microscopy, animals were perfused at 21
dpl with 4% glutaraldehyde in PBS containing 0.4 mM
CaCl2 and postfixed in the same solution at 4°C. The
spinal cord was coronally sliced at 1-mm thickness and
treated with 2% osmium tetroxide overnight before being
subjected to a standard protocol for epoxy resin embed-
ding (Zhao et al. 2008) Tissues were sectioned at 1 m
and stained with toluidine blue. Remyelination ranking, in
which lesions with the greatest extent of remyelination
were assigned the highest rank value, was performed
under light microscopy (Ibanez et al. 2003). Ultrathin sec-
tions of the lesion site were cut onto copper grids and
stained with uranyl acetate before being examined with a
Hitachi H-600 transmission electron microscope. G-ratio
was quantified on 50-nm sections on a minimum of 70
myelinated and remyelinated axons per animal, three to
five mice for each genotype.
Statistical analysis
All statistical analyses were done using GraphPad
Prism (Table 1). Unpaired Student’s t test was used for
every two datasets with equal variances and for which
data followed a normal distribution. If data were not nor-
mally distributed, nonparametric Mann–Whitney test was
used (for rankings analysis), and if the variances were
significantly different, the Welch’s correction was applied
(for g-ratio analysis). Two-way ANOVA was used to com-
pare three or more sets of data. For all graphs, error bars
are mean  SEM.
Results
DNA methyltransferases are differently expressed in
adult OPCs during remyelination
To begin characterizing the role of DNA methylation in
the oligodendroglial lineage during remyelination, we per-
formed lysolecithin injections in the ventrolateral spinal
cord of 8-week-old C57BL/6 mice and perfused them at
5, 14, and 21 dpl, to access DNMT1, DNMT3A, and 5mC
expression in OPCs and OLs (Fig. 1A). The number of
NKX2.2 oligodendroglial cells strongly expressing DNMT1,
while abundant at 5 dpl when compared with levels in
surrounding intact nonlesioned white matter (NWM), de-
creased between 5 and 21 dpl (Fig. 1B, C). Costaining of
DNMT1 with CC1, a marker of mature OLs, or NKX2.2, a
marker of OPCs, revealed that within the CC1 population
the enzyme was expressed in 35.3  6.3% (5 dpl), 12.0 
5.4% (14 dpl), and 9.2  5.6% (21 dpl) of cells, whereas
in the NKX2.2 population, it was expressed in 74.6 
5.3% (5 dpl), 57.3  11.1% (14 dpl), and 49.4  4.0% (21
dpl) of cells (Fig. 1B, D). In contrast, the distribution of
DNMT3A showed a different pattern, being strongly ex-
pressed by CC1 cells and increased from 5 to 14 dpl
(Fig. 1E, F): DNMT3A was expressed in 81.0  7.6% (5
dpl), 97.8  1.9% (14 dpl), and 74.0  9.3% (21dpl) of the
CC1 OL population and in only 17.4  3.8% (5 dpl),
14.7  4.0% (14 dpl), and 6.7  4.4% (21 dpl) of the
NKX2.2 population (Fig. 1E, G). These data indicate
distinct patterns of expression, with DNMT1 mainly
expressed by adult OPCs during the early stages of
remyelination, and DNMT3A mainly detected in differ-
entiated adult OLs that appear in the later stages of
remyelination.
We also quantified 5mC expression levels in oligoden-
droglial cells. Because of species similarities in the 5mC
antibodies and those we had used for the OL lineage, we
combined 5mC staining with the pan-OL lineage marker
OLIG2. This revealed a decreased proportion of low-
methylated and increased proportion of medium- and
high-methylated oligodendroglial cells during remyelina-
tion (Fig. 1H, I). Hypermethylation in OLIG2 cells was
already evident starting at 5 dpl (Fig. 1I).
Ablation of DNMT3A and both DNMT1 and 3A
impairs oligodendrocyte differentiation during
remyelination
To address more specifically the functional role of DNA
methylation in adult OPCs during remyelination, we
continued
5, 14, and 21 dpl (white arrowheads indicate double-positive cells). F, Quantification of the number of double DNMT3A and CC1
cells at 5, 14, and 21 dpl, compared with NWMc. G, Quantification of the percentage of double DNMT3A and NKX2.2 or CC1 cells
at 5, 14, and 21 dpl, compared with NWMd. H, Representative 5mC and OLIG2 staining in NWM and at 5, 14, and 21 dpl (white
arrowheads indicate high-5mC/OLIG2 cells). Representative low-, medium-, and high-5mC cells are shown below. I, Quantification
of low-, medium-, and high-5mC levels in OLIG2 cells at 5, 14, and 21 dpl, compared with NWMe. Scale bar 20 m. Data are mean
SEM. n  4–6 animals, three sections per animal. p  0.05, p  0.01, p  0.001 (ANOVA).
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crossed the Dnmt1fl/fl and Dnmt3afl/fl lines with the induc-
ible Plp-creER(t), to target specific ablation of Dnmt1,
Dnmt3a, or both Dnmt1 and Dnmt3a in proteolipid protein
(PLP)-expressing oligodendroglial cells after lysolecithin-
induced demyelination. All three mutants (PlpcreER(t)/:
Dnmt1fl/fl; PlpcreER(t)/:Dnmt3afl/fl; and PlpcreER(t)/:Dnmt1fl/fl;
Dnmt3afl/fl) and control littermates (Plp/:Dnmt1fl/fl; Plp/:
Dnmt3afl/fl and Plp/:Dnmt1fl/fl;Dnmt3afl/fl) were gavaged
with tamoxifen at 3, 5, and 7 dpl and then lesion-
containing tissue harvested at 14 dpl and processed for
immunohistochemistry using antibodies specific for 5mC,
for mature oligodendrocytes (CC1), or for all cells within
the oligodendrocyte lineage (OLIG2).
We first quantified the number of OLIG2 and CC1 in
NWM to address the effect of Dnmt1 and/or Dnmt3a
ablation itself on the generation of OPCs and OLs (Fig.
2A–F). We detected no difference in the number of
OLIG2 and CC1 cells in any knock-out compared with
control NWM (Fig. 2B, D, F). Moreover, there was no
differences in 5mC expression levels in OLIG2 cells in
knock-out compared with control NWM (Fig. 2G–J).
At 14 dpl, there was no difference in the number of
OLIG2 and CC1 cells in the lesion or in the percentage
of CC1 differentiated OL among the OLIG2 oligoden-
droglial cells between Plp/;Dnmt1fl/fl controls and
PlpcreER(t)/;Dnmt1fl/fl mutants (Fig. 3A, B). Ablation of
Dnmt3a resulted in a significant decrease of the percent-
age of CC1 differentiated OL among the OLIG2 oligo-
dendroglial cells (Fig. 3C, D). This indicated that OPC
differentiation was altered in mutants lacking Dnmt3a,
whereas OLIG2 proliferation and recruitment to the le-
sion was not affected (Fig. 3D). It was noteworthy that
increased DNMT1 levels were detected in CC1 cells in
PlpcreER(t)/;Dnmt3afl/fl mutant spinal cords, suggesting
that in the absence of DNMT3A there might be a com-
pensatory increase in DNMT1 (Fig. 3G). To offset this
possible effect, we performed a similar analysis on double
knockout mice lacking both Dnmt1 and Dnmt3a. Both the
number of CC1 cells in the lesion and the percentage of
CC1 differentiated OL among the OLIG2 oligodendro-
glial cells were decreased in the double (PlpcreER(t)/:
Dnmt1fl/fl;Dnmt3afl/fl)mutants, and to a greater extent than
we observed in the Dnmt3a-only ablated (PlpcreER(t)/;
Dnmt3afl/fl) mutants (Fig. 3E, F).
There were no changes in 5mC expression levels in
OLIG2 cells in PlpcreER(t)/;Dnmt1fl/fl and PlpcreER(t)/;
Dnmt3afl/fl mutants (Fig. 4A–D). However, there was an
increase in the percentage of low-5mC–expressing
OLIG2 cells, associated with a decrease of medium-
5mC–expressing OLIG2 cells in the double PlpcreER(t)/:
Dnmt1fl/fl;Dnmt3afl/fl mutants (Fig. 4E, F). This suggested
an increase in low-methylated and a decrease in medium-
methylated oligodendroglial cells in Dnmt1/Dnmt3a ab-
lated mutants, which contrasted with the increased
methylation previously observed in control animals (Fig.
1H, I).
These data indicate a role for DNMT3A in adult OPC
differentiation during remyelination that can be compen-
sated for by DNMT1.
Ablation of Dnmt1 and Dnmt3a impairs
remyelination in the adult spinal cord
To establish whether the impaired differentiation of OPC
lacking DNMTs affected remyelination, we used a similar
experimental design where we killed lesioned control and
mutant mice at 21 dpl and evaluated remyelination by light
microscopic examination of semithin resin sections stained
with toluidine blue and by electron microscopy. Comparison
of control and mutant NWM revealed no abnormalities in
myelination in the three knockout mouse lines (data not
shown). Ranking of remyelination on semithin sections (Fig.
3A, B, D, E) and quantification of the g-ratio (Fig. 3C, F) did
not reveal any differences from controls for either Dnmt1- or
Dnmt3a-ablated mice. In contrast, despite a similar ranking
of remyelination in sections from controls and double mu-
tants (both Dnmt1 and Dnmt3a ablated; Fig. 3G, H, J), the
quantification of g-ratio revealed thinner myelin in mutants,
likely suggesting delayed remyelination in the absence of
Dnmt1 and Dnmt3a (Fig. 3I). This suggests that if Dnmt3a-
only ablation is sufficient to reduce adult OPC differentiation
in a lysolecithin-induced lesion, compensation by DNMT1
might prevent significantly delayed remyelination.
These data demonstrate that dysregulation of DNA methyl-
ation in adult oligodendroglial cells impairs their differentiation
and hence their ability to contribute to remyelination.
Discussion
Here we report that DNMT1 and DNMT3A are differen-
tially expressed during remyelination after lysolecithin-
induced demyelination in the adult spinal cord, with
DNMT1 being highly expressed in OPCs at early time
points after demyelination (corresponding in this model to
the early stages of remyelination) and DNMT3A being
highly expressed in OL at later time points (corresponding
Figure 2. Ablation of Dnmt1 or Dnmt3a does not impair oligodendrocyte differentiation or their methylation levels in control conditions.
A, Representative OLIG2 and CC1 staining in tamoxifen-treated Plp/;Dnmt1fl/fl and PlpcreER(t)/;Dnmt1fl/fl NWM spinal cords. B,
Quantification of OLIG2 and CC1 cell densities in NWMf (p  0.3537, p  0.3803). C, Representative OLIG2 and CC1 staining in
tamoxifen-treated Plp/;Dnmt3afl/fl and PlpcreER(t)/;Dnmt3afl/fl NWM spinal cords. D, Quantification of OLIG2 and CC1 cell
densities in NWMg (p  0.8926, p  0.5109). E, Representative OLIG2 and CC1 staining in tamoxifen-treated Plp/;Dnmt1fl/fl;
Dnmt3afl/fl and PlpcreER(t)/;Dnmt1fl/fl;Dnmt3afl/fl NWM spinal cords. F, Quantification of OLIG2 and CC1 cell densities in NWMh
(p  0.3136, p  0.2173). G, Representative 5mC and OLIG2 stainings in tamoxifen-treated PlpcreER(t)/;Dnmt1fl/fl, PlpcreER(t)/;Dnmt3afl/fl,
and PlpcreER(t)/;Dnmt1fl/fl;Dnmt3afl/fl NWM spinal cords (white arrowheads indicate high-5mC/OLIG2 cells). H, Quantification of
low-, medium-, and high-5mC levels in OLIG2 cells in tamoxifen-treated Plp/;Dnmt1fl/fl and PlpcreER(t)/;Dnmt1fl/fl NWMj. I,
Quantification of low-, medium-, and high-5mC levels in OLIG2 cells in tamoxifen-treated Plp/;Dnmt3afl/fl and PlpcreER(t)/;
Dnmt3afl/fl NWMjj. J, Quantification of low-, medium-, and high-5mC levels in OLIG2 cells in tamoxifen-treated Plp/;Dnmt1fl/fl;
Dnmt3afl/fl and PlpcreER(t)/;Dnmt1fl/fl;Dnmt3afl/fl NWMk. Scale bar  50 m. Data are mean  SEM. n  4–6 animals, three sections
per animal (Student’s t test, ANOVA).
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Figure 3. Ablation of Dnmt3a and both Dnmt1 and Dnmt3a impairs oligodendrocyte differentiation during remyelination. A,
Representative OLIG2 and CC1 staining at 14 dpl in tamoxifen-treated Plp/;Dnmt1fl/fl and PlpcreER(t)/;Dnmt1fl/fl spinal cords. B,
Quantification of OLIG2 and CC1 cell densities and CC1/OLIG2 cells percentage at 14 dpll (p 0.7955, p 0.3573, p 0.9689).
C, Representative OLIG2 and CC1 staining at 14 dpl in tamoxifen-treated Plp/;Dnmt3afl/fl and PlpcreER(t)/;Dnmt3afl/fl spinal cords.
D, Quantification of OLIG2 and CC1 cell densities and CC1/OLIG2 cells percentage at 14 dplm (p  0.7851, p  0.0550, p 
0.0149). E, Representative OLIG2 and CC1 staining at 14 dpl in tamoxifen-treated Plp/;Dnmt1fl/fl;Dnmt3afl/fl and PlpcreER(t)/;
Dnmt1fl/fl;Dnmt3afl/fl spinal cords. F, Quantification of OLIG2 and CC1 cell densities and CC1/OLIG2 cells percentage at 14 dpln
(p  0.1510, p  0.0357, p  0.0006). G, Quantification of DNMT1 and DNMT3A expression in CC1 cells at 14 dpl in
tamoxifen-treated Plp/;Dnmt1fl/fl and PlpcreER(t)/;Dnmt1fl/fl, Plp/;Dnmt3afl/fl and PlpcreER(t)/;Dnmt3afl/fl, Plp/;Dnmt1fl/fl;
Dnmt3afl/fl and PlpcreER(t)/;Dnmt1fl/fl;Dnmt3afl/fl spinal cords, to detect eventual compensation between DNMTs at the protein level°
(p  0.0075, p  0.0505, p  0.0074, p  0.0053, p  0.0072, p  0.0012). Scale bar  20 m. Data are mean  SEM. n  4–6
animals, three sections per animal. p  0.05, p  0.01, p  0.001 (Student’s t test).
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to the later stages and completion of remyelination).
These data validate and extend previous microarray-
generated data obtained in laser-capture microdissected
tissues from rats with ethidium bromide–induced demy-
elinating lesions, which revealed initial increased expres-
sion of both Dnmt1 and Dnmt3a and their subsequent
decrease in expression (Huang et al. 2011). Discordance
between the two studies, especially for DNMT3A expres-
sion, can be explained by differences in the experimental
approach. The Huang et al. (2011) dataset was obtained
from whole tissue, which has a mixed composition and
percentage of various cell types at different time points,
possibly impacting the levels of transcripts. Indeed,
Dnmt1 and Dnmt3a are also highly expressed by astro-
cytes and microglial cells, the latter being massively abun-
dant in the lesion at 5 dpl but less abundant during later
stages (Zhang et al. 2014).
Our study reports global hypermethylation in the nuclei
of oligodendroglial lineage cells during remyelination, sim-
ilar to what was described during developmental myeli-
nation (Moyon et al. 2016). These data suggested that
adult OPC differentiation might recapitulate their develop-
mental differentiation, by activating the same transcrip-
tional pathways and perhaps the same epigenetic
modulators (Fancy et al. 2004, 2009; Koenning et al. 2012;
Nakatani et al. 2013; Moyon et al. 2015; Zhao et al. 2015).
Indeed, chromatin remodelers (i.e., Chd7 and Brg1) and
histone deacetylases have been recently shown to be
Figure 4. Ablation of Dnmt3a and both Dnmt1 and Dnmt3a impairs methylation levels in oligodendroglial cells during remyelination.
A, Representative 5mC and OLIG2 staining at 14 dpl in tamoxifen-treated Plp/;Dnmt1fl/fl and PlpcreER(t)/;Dnmt1fl/fl spinal cords
(white arrowheads indicate high-5mC/OLIG2 cells). B, Quantification of low-, medium-, and high-5mC levels in OLIG2 cells at
14dplp. C, Representative 5mC and OLIG2 staining at 14 dpl in tamoxifen-treated Plp/;Dnmt1fl/fl and PlpcreER(t)/;Dnmt3afl/fl spinal
cords (white arrowheads indicate high-5mC/OLIG2 cells). D, Quantification of low-, medium-, and high-5mC levels in OLIG2 cells
at 14dplq. E, Representative 5mC and OLIG2 staining at 14 dpl in tamoxifen-treated Plp/;Dnmt1fl/fl and PlpcreER(t)/;Dnmt1fl/fl;
Dnmt3afl/fl spinal cords (white arrowheads indicate high-5mC/OLIG2 cells). F, Quantification of low-, medium-, and high-5mC
levels in OLIG2 cells at 14 dplr. Scale bar 100 m. Data are mean SEM. n 4–6 animals, three sections per animal. p 0.01,
p  0.001 (ANOVA).
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essential for OPC myelination as well as remyelination
(Shen et al. 2008; He et al. 2016).
Using conditional knockout murine strains, we showed
that lack of Dnmt3a, and not Dnmt1, in oligodendroglial
cells impairs adult OPC differentiation. These data dif-
fered from the findings obtained during development,
when the ablation of Dnmt1, and not Dnmt3a, resulted in
extensive defective myelination of the CNS (Moyon et al.
Figure 5. Ablation of Dnmt1 and Dnmt3a impairs remyelination in the adult spinal cord. A, Representative semithin sections at 21 dpl
in tamoxifen-treated Plp/;Dnmt1fl/fl and PlpcreER(t)/;Dnmt1fl/fl spinal cords. B, Relative ranking of remyelinations (p  0.3075). C,
Quantification of g-ratios for control and mutants mice, and plot of g-ratios against axonal diametert (p  0.9426). D, Representative
semithin sections at 21 dpl in tamoxifen-treated Plp/;Dnmt3afl/fl and PlpcreER(t)/;Dnmt3afl/fl spinal cords. E, Relative ranking of
remyelinationu (p  0.7144). F, Quantification of g-ratios for control and mutants mice, and plot of g-ratios against axonal diameterv
(p  0.1079). G, Representative semithin sections at 21 dpl in tamoxifen-treated Plp/;Dnmt1fl/fl;Dnmt3afl/fl and PlpcreER(t)/;Dnmt1fl/fl;
Dnmt3afl/fl spinal cords. H, Relative ranking of remyelinationx (p  0.7584). I, Quantification of g-ratios for control and mutants mice,
and plot of g-ratios against axonal diametery (p  0.0005). J, Representative electron microscopic sections at 21 dpl in tamoxifen-
treated Plp/;Dnmt1fl/fl;Dnmt3afl/fl and PlpcreER(t)/;Dnmt1fl/fl;Dnmt3afl/fl spinal cords revealing new thin myelin sheaths of remyeli-
nation (arrows) and a demyelinated axon (arrowhead). Scale bar  10 m. Dots are ranking for each mouse (B, E, H) and g-ratio for
each quantified axon (C, F, I). Data are mean  SEM. n  3–5 animals, 70 axons per animal. p  0.01 (Mann–Whitney test and
Student’s t test).
New Research 10 of 12
March/April 2017, 4(2) e0336-16.2017 eNeuro.org
2016). We also observed that, contrary to developmental
data, loss of Dnmt3a was partially compensated for by
upregulation of Dnmt1 levels, leading to decreased adult
OPC differentiation and remyelination delays in the double
conditional knockout mice. It is important to highlight that
the Plp-creER(t) line was used to target oligodendroglial
lineage in an inducible manner in the adult spinal cord.
Although PLP has been shown to be expressed in adult
OPCs (Spassky et al. 1998; Ruffini et al. 2004; Lin et al.
2009), our ablation of Dnmt1 and Dnmt3a may have tar-
geted a more mature population, when cells have already
exited the cell cycle, and thus when DNMT1 and DNMT3A
might have a different impact. The remyelination delay
observed here is also less drastic than the extensive and
global hypomyelination affecting the Olig1cre/;Dnmt1fl/fl
mutant mice (Moyon et al. 2016). Adult OPCs tend to
proliferate less than their neonatal counterparts, suggest-
ing that the absence of DNMT1 may not as adversely
affect their replication, cell division, and survival (Wolswijk
and Noble, 1989; Wolswijk et al. 1991; Shi et al. 1998;
Ruffini et al. 2004; Lin et al. 2009; Young et al. 2013;
Moyon et al. 2015). Moreover, some epigenetic marks
might have been already established and could be irre-
versibly maintained in adult OPCs, which are emerging
from a pool of undifferentiating neonatal OPCs (Zawadzka
et al. 2010). Indeed, it has been shown that in cell lines
epigenetic markers such as histone methylation, histone
deacetylation, and DNA methylation might have specific
dynamics, with some being partial committers and others
complete committers, depending on their enzyme recruit-
ment speed and affinity at specific genomic sites (Bintu
et al. 2016). For example, the de novo embryonic
DNMT3B is a slow silencer but complete committer, as its
methylated marks could not be easily removed. Thus, it
could explain why ablation of Dnmt3a in adult OPCs might
have a limited effect and only delay remyelination, as its
markers would be maintained long after the enzyme ab-
lation.
Finally, DNA methylation has been shown to be dys-
regulated in several neurologic pathologies, including
amyotrophic lateral sclerosis, schizophrenia, and oligo-
dendroglial pathologies such as MS and gliomas (Chou
et al. 2012; Martin and Wong, 2013; Huynh et al. 2014;
Hannon et al. 2016; Jaffe et al. 2016). In addition to
neuropathy, dementia, and hearing loss, patients with
DNA methyltransferase (DNMT1) mutations present with
mild CNS hypomyelination (Klein et al. 2011). Epigenome-
wide methylation study has identified several hypermethy-
lated or hypomethylated loci in MS patient postmortem
brain tissues compared with controls (Huynh et al. 2014)
and several studies in gliomas have described an extensive
global DNA hypomethylation (Watanabe and Maekawa, 2010;
Chou et al. 2012) associated with site-specific DNA hy-
permethylation (Felsberg et al. 2006; Sharma et al. 2010).
Further epigenome-wide studies should be performed on
adult OPCs to specifically identify genomic loci that might
be hypo- or hypermethylated during their proliferation
and their differentiation, in control conditions and after
demyelination or in gliomas. We propose that modulat-
ing DNA methylation in oligodendroglial cells could
efficiently regulate adult OPC proliferation and differen-
tiation capacities. Targeting DNA methylation at spe-
cific genomic loci, using engineered zinc fingers or
CRISPR-Cas9 methylation modulators, might lead to
the development of new therapeutic strategies in glio-
mas and MS (Choudhury et al. 2014; Heller et al. 2014;
McDonald et al. 2016).
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